Company intelligence

CGON

CG Oncology, Inc. Common stock · NASDAQ · Healthcare

Price$78.44-0.65% · −$0.51

Market cap6.92BEquity value

P / E-29.2Trailing ratio

Volume109.52KLatest session

Market data

CGON price chart

TradingView

Related signals

1 min delayed

Browse public CGON signals with their source context and measured market impact. Open any signal for its permanent analysis page.

CGONMay 11, 2026+3.24% since signal

CG Oncology Reports Mixed Q1 Earnings and Analyst Target Upgrades

CG Oncology's Q1 results showed an unexpected loss, but sales exceeded expectations. Analyst upgrades of price targets suggest continued confidence in the stock's potential despite recent earnings performance.

View signal analysis

CGONSep 8, 2025-1.70% since signal

CG Oncology Stock Signals Bullish Momentum Ahead

CGON enters Phase 2, indicating potential bullish momentum. The Buddhi period follows consolidation, increasing breakout likelihood. CGON has rallied 24% since initiating the Buddhi phase. Investors should note large funds taking positions in CGON. Bullish projections extend through April 2026 due to established patterns.

View signal analysis

CGONApr 28, 2025-9.06% since signal

CG Oncology's Bladder Cancer Drug Impresses Investors - Here's Why

CGON presents data for cretostimogene at 2025 Urological Association Meeting. 75.5% complete response seen in high-risk NMIBC patients. 97.3% of patients were free from disease progression at 24 months. No serious treatment-related adverse events were reported. CGON stock surged 39.9% to $31.30 following this news.

View signal analysis

Research